Educational guide
Epitope Mapping in Antibody Therapeutics and Vaccine Development: The Evolving Landscape
- Time: Understanding the precise binding sites of antibodies on their target antigens can significantly advance the discovery and development of new therapeutics and vaccines, providing critical insights into mechanisms of action and protection. While there a
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
- Time:
Understanding the precise binding sites of antibodies on their target antigens can significantly advance the discovery and development of new therapeutics and vaccines, providing critical insights into mechanisms of action and protection. While there are numerous approaches for epitope mapping, comprehensive, high-throughput mutagenesis has emerged as a leading technique for both conformational and linear epitopes that couples high-resolution results with the speed that the biopharmaceutical industry demands.
Epitopes have also become paramount for intellectual property considerations, such as patentability or freedom to operate evaluations. Both patents and regulatory submissions have been strengthened by the knowledge of specific binding site information. However, recent changes to intellectual property and regulatory laws surrounding epitope patentability and biosimilars necessitate adjusting antibody IP strategies.
Our panelists for this webinar will discuss the importance of epitope mapping in drug and vaccine discovery from the scientific as well as the legal perspectives.
Joseph Rucker, Ph.D., VP of R&D at Integral Molecular, will discuss Shotgun Mutagenesis, a high-throughput mutagenesis approach for epitope mapping conformational epitopes on structurally complex proteins such as GPCRs.
James E. Crowe, Jr., M.D., Professor at the Vanderbilt University Medical Center, will present his research demonstrating novel mechanisms of action for neutralizing antibodies targeting viral envelope proteins. The importance of epitope mapping for identifying targetable viral structures will be discussed in the context of vaccine discovery.
Lisa A. Haile, J.D., Ph.D., Partner at DLA Piper, will provide an update on the intellectual property landscape and what is currently protectable by patents with respect to antibodies and their epitopes.
Who Should Attend
- Scientists involved in therapeutic antibody discovery
- Scientists involved in vaccine discovery
- Biopharmaceutical business development personnel
- Regulatory affairs personnel
- Intellectual property attorneys
You Will Learn
- The latest techniques being used for epitope mapping.
- How epitopes are being solved for difficult targets and large collections of antibodies.
- How epitope mapping data can provide critical insights into the mechanism of action of therapeutic antibodies and vaccines.
- How recent changes to intellectual property laws have affected what is patentable.
Produced with support from:
Panelists
Joseph Rucker, Ph.D. VP of Research and Development, Integral Molecular
James E Crowe, Jr., M.D. Professor of Pediatrics Microbiology and Immunology, Vanderbilt University Medical Center
Lisa A. A. Haile, J.D., Ph.D. Partner, DLA Piper, Co-Chair, Global Life Sciences Sector